These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 237589)

  • 21. Evaluation of four coagulation tests to detect plasma lupus anticoagulants.
    Saxena R; Saraya AK; Kotte VK; Singh YN; Prasad L; Malviya AN
    Am J Clin Pathol; 1991 Dec; 96(6):755-8. PubMed ID: 1746492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The lupus anticoagulant. A disease marker in antinuclear antibody negative lupus that is cross-reactive with autoantibodies to double-stranded DNA.
    Colaco CB; Elkon KB
    Arthritis Rheum; 1985 Jan; 28(1):67-74. PubMed ID: 3917672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal IgG anticoagulants delaying fibrin aggregation in two patients with systemic lupus erythematosus (SLE).
    Galanakis DK; Ginzler EM; Fikrig SM
    Blood; 1978 Nov; 52(5):1037-46. PubMed ID: 698389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies on a circulating anticoagulant inhibiting factor XI in a patient with congenital deficiency and carcinoma of the prostate.
    Chediak J; Madej-Zevin P; Ratnoff OD; Goldsmith GH; Everson B
    Br J Haematol; 1986 May; 63(1):123-33. PubMed ID: 3486671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating anticoagulant against factors XI and XII together with massive spontaneous platelet aggregation.
    Cronberg S; Nilsson IM
    Scand J Haematol; 1973; 10(4):309-14. PubMed ID: 4587560
    [No Abstract]   [Full Text] [Related]  

  • 26. Platelet function and coagulation profile in lupus erythematosus. Studies in 50 patients.
    Regan MG; Lackner H; Karpatkin S
    Ann Intern Med; 1974 Oct; 81(4):462-8. PubMed ID: 4213298
    [No Abstract]   [Full Text] [Related]  

  • 27. Human factor XIa cleaves fibrinogen: effects on structure and function.
    Scott CF; Mentzer RL; Budzynski AZ; Colman RW
    Arch Biochem Biophys; 1986 Sep; 249(2):480-8. PubMed ID: 2944482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases.
    Gastineau DA; Kazmier FJ; Nichols WL; Bowie EJ
    Am J Hematol; 1985 Jul; 19(3):265-75. PubMed ID: 3925759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Some properties of autoprothrombin II-A anticoagulant.
    Emekli NB; Ulutin ON
    Bibl Haematol; 1977; 44():15-20. PubMed ID: 617778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coagulation tests and anti-phospholipid antibodies in patients positive for lupus anticoagulant.
    Sakakura M; Wada H; Watanabe R; Mamamuro M; Okugawa Y; Nakasaki T; Nakase T; Wakita Y; Minamikawa K; Mori Y; Nshikawa M; Shiku H
    Clin Appl Thromb Hemost; 2000 Jul; 6(3):144-50. PubMed ID: 10898274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anticoagulant mechanism of sulfonated polyisoprenes.
    Tamada Y; Murata M; Hayashi T; Goto K
    Biomaterials; 2002 Mar; 23(5):1375-82. PubMed ID: 11804293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis.
    Laudes IJ; Chu JC; Sikranth S; Huber-Lang M; Guo RF; Riedemann N; Sarma JV; Schmaier AH; Ward PA
    Am J Pathol; 2002 May; 160(5):1867-75. PubMed ID: 12000738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lupus anticoagulants: improved diagnosis with a kaolin clotting time using rabbit brain phospholipid in standard and high concentrations.
    Rosove MH; Ismail M; Koziol BJ; Runge A; Kasper CK
    Blood; 1986 Aug; 68(2):472-8. PubMed ID: 3730611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The thrombin activation pathway modulates the assembly, structure and lysis of human plasma clots in vitro.
    Torbet J
    Thromb Haemost; 1995 May; 73(5):785-92. PubMed ID: 7482404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A circulating anticoagulant directed against factor XIa in systemic lupus erythematosus.
    DiSabatino CA; Clyne LP; Malawista SE
    Arthritis Rheum; 1979 Oct; 22(10):1135-8. PubMed ID: 486223
    [No Abstract]   [Full Text] [Related]  

  • 36. Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants.
    Glueck HI; Kant KS; Weiss MA; Pollak VE; Miller MA; Coots M
    Arch Intern Med; 1985 Aug; 145(8):1389-95. PubMed ID: 3927865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies on a circulating anticoagulant in procainamide-induced lupus erythematosus.
    Edwards RL; Rick ME; Wakem CJ
    Arch Intern Med; 1981 Nov; 141(12):1688-90. PubMed ID: 6171218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new exogen anticoagulant with high selectivity to intrinsic pathway of coagulation.
    de Araújo RM; Vaz AF; Santos ME; Zingali RB; Coelho LC; Paiva PM; Correia MT; Oliva ML; Ferreira RS
    Thromb Res; 2011 Oct; 128(4):395-7. PubMed ID: 21752431
    [No Abstract]   [Full Text] [Related]  

  • 39. Theory of blood coagulation in disseminated intravascular coagulation (D. I. C.).
    Murano G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1972; 97(1):5-19. PubMed ID: 4114585
    [No Abstract]   [Full Text] [Related]  

  • 40. Impaired control of the tissue factor pathway of blood coagulation in systemic lupus erythematosus.
    Adams MJ; Palatinus AA; Harvey AM; Khalafallah AA
    Lupus; 2011 Dec; 20(14):1474-83. PubMed ID: 21993387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.